论文部分内容阅读
1993年9月有幸受邀赴美就肿瘤基因治疗临床应用进行考察,参观了几家研究所和医院,与承担美国RAC/FDA批准的肿瘤基因治疗项目的主要专家进行了学术交流,从而对美国肿瘤基因治疗的临床项目开展情况有一初步印象。 1 已批准的基因治疗临床项目概况 RAC已批准68项,FDA批准其中的56项,除荷兰2项,中国、法国、意大利各1项外,其余均为美国申请项目。从RAC批准项目的进程看,1989年到1993年批准项目逐年成倍增加。在这些项目中除12项为遗传病,6项为病毒性疾病(艾滋病)外,其余均为肿瘤。因此足见在整个基因治疗中肿瘤基因治疗占有十分重要地位。
In September 1993, he was honored to be invited to the United States to investigate the clinical application of oncogene therapy, visited several research institutes and hospitals, and conducted academic exchanges with key experts who undertook RAC/FDA-approved cancer gene therapy projects in the United States. There is a preliminary impression of the development of clinical programs for tumor gene therapy. 1 Approved Gene Therapy Clinical Project Overview RAC has approved 68 items and FDA approved 56 of them. Except 2 items in the Netherlands, 1 in China, France, and Italy, the rest are US applications. Judging from the process of RAC approval of projects, the number of projects approved from 1989 to 1993 has multiplied year by year. Of these items, except for 12 genetic diseases and 6 viral diseases (AIDS), the rest are tumors. Therefore, it is considered that cancer gene therapy plays a very important role in the entire gene therapy.